Alseres Pharmaceuticals, Inc.
ALSE · OTC
12/31/2013 | 12/31/2012 | 12/31/2011 | 12/31/2010 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $114 | $17 | $136 | $99 |
| Short-Term Investments | $207 | $881 | $27 | $96 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $14 | $3 | $5 | $14 |
| Total Curr. Assets | $325 | $900 | $168 | $209 |
| Property Plant & Equip (Net) | $0 | $1 | $2 | $48 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $204 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $61 | $65 | $0 | $0 |
| Total NC Assets | $61 | $66 | $2 | $252 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $385 | $966 | $171 | $461 |
| Liabilities | – | – | – | – |
| Payables | $500 | $2,197 | $0 | $3,577 |
| Short-Term Debt | $0 | $6,410 | $27,728 | $33,726 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $74 | $74 | $0 | $0 |
| Other Curr. Liab. | $1,075 | $1,386 | $2,697 | $4,985 |
| Total Curr. Liab. | $1,648 | $10,067 | $30,425 | $42,288 |
| LT Debt | $7,820 | $0 | $0 | $31 |
| Deferred Rev, NC | $1,143 | $1,217 | $0 | $0 |
| Deferred Tax Liab, NC | $390 | $0 | $0 | $0 |
| Other NC Liab. | $44 | $16,403 | $0 | $5,428 |
| Total NC Liab. | $9,397 | $17,620 | $348 | $5,459 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $96 |
| Total Liabilities | $11,045 | $27,687 | $30,773 | $47,747 |
| Equity | – | – | – | – |
| Pref Stock | $390 | $0 | $0 | $0 |
| Common Stock | $306 | $306 | $306 | $268 |
| Retained Earnings | -$199,635 | -$198,694 | -$197,048 | -$194,166 |
| AOCI | $7 | -$309 | -$31 | $0 |
| Other Equity | $188,662 | $172,345 | $166,519 | $146,612 |
| Total Equity | -$10,660 | -$26,721 | -$30,602 | -$47,286 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $385 | $966 | $171 | $461 |
| Net Debt | $7,706 | $6,393 | $27,592 | $33,658 |